A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation
Biotechnology Journal · 2024
DOI: 10.1002/biot.202300323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Benjamin Kogelmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria. Hauptthemen laut MEDLINE: Glycoproteins, UDP Xylose-Protein Xylosyltransferase. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Centre of Industrial Biotechnology, Austrian Science Fund.
Abstract (Originalsprache)
Control over glycosylation is an important quality parameter in recombinant protein production. Here, we demonstrate the generation of a marker‐free genome edited Nicotiana benthamiana N‐glycosylation mutant (NbXF‐KO) carrying inactivated β1,2‐xylosyltransferase and α1,3‐fucosyltransferase genes. The knockout of seven genes and their stable inheritance was confirmed by DNA sequencing. Mass spectrometric analyses showed the synthesis of N‐glycans devoid of plant‐specific β1,2‐xylose and core α 1,3‐fucose on endogenous proteins and a series of recombinantly expressed glycoproteins with different complexities. Further transient glycan engineering towards more diverse human‐type N‐glycans resulted in the production of recombinant proteins decorated with β1,4‐galactosylated and α2,6‐sialylated structures, respectively. Notably, a monoclonal antibody expressed in the NbXF‐KO displayed glycosylation‐dependent activities. Collectively, the engineered plants grow normally and are well suited for upscaling, thereby meeting industrial and regulatory requirements for the production of high‐quality therapeutic proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria.
- acib - Austrian Centre of Industrial Biotechnology, Vienna, Austria.
- Medicago Inc., Quebec, Quebec, Canada.
- Division of Infectious Diseases, University of California, Irvine, Irvine, California, USA.
ORCID-Profile: Benjamin Kogelmann, Eva Stöger, Richard Strasser
Förderung
- Austrian Centre of Industrial Biotechnology
- Austrian Science Fund
Zitieren
APA
Kogelmann, B., Melnik, S., Bogner, M., Kallolimath, S., Stöger, E., Sun, L., Strasser, R., D'Aoust, M. A., Lavoie, P. O., Saxena, P., Gach, J. S., & Steinkellner, H. (2024). A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation. Biotechnology Journal. https://doi.org/10.1002/biot.202300323
Vancouver
Kogelmann B, Melnik S, Bogner M, Kallolimath S, Stöger E, Sun L, et al. A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation. Biotechnology Journal. 2024. doi:10.1002/biot.202300323
BibTeX
@article{Kogelmann2024,
author = {Kogelmann, Benjamin and Melnik, Stanislav and Bogner, Michaela and Kallolimath, Somanath and Stöger, Eva and Sun, Lin and Strasser, Richard and D'Aoust, Marc-André and Lavoie, Pierre-Olivier and Saxena, Pooja and Gach, Johannes S and Steinkellner, Herta},
title = {A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202300323}
}
EUVIMED